Communication from Polymer Factory Sweden AB’s Annual General Meeting 2023

Annual General Meeting in Polymer Factory Sweden AB (publ) was held 2 June 2023, 13.00 at the Company’s premises. Summarized below are the most important decisions from the Annual General Meeting.

Adoption of the profit and loss statement and the balance sheet
The Annual General Meeting adopted the profit and loss statement and the balance sheet for the Company for the financial year 2022.

The company’s profits or losses according to the adopted balance sheet
The Annual General Meeting resolved that the Company’s results shall be carried forward in new account and that no dividend shall be paid for the financial year 2022.

The members of the board of directors’ and the CEO’s discharge from liability
The Annual General Meeting resolved that the Board of Directors and the CEO shall be discharged from liability for the financial year 2022.

Determination of the fees payable to the members of the board of directors and the auditor
In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved that the fees to the Board of Directors, until the end of the next annual general meeting, shall amount to SEK 155,000 to be distributed between the members of the Board of Directors who are not employed by the Company or related party to an employee of the Company.

The Annual General Meeting also resolved that fees to the auditor are paid in accordance with approved invoices and customary billing standards.

Election of members of the board of directors and auditor
In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved to re-elect Leif Gustafsson, Anders Hult, Michael Malkoch, Mats Wallnér and Eva Malmström Jonsson as members of the Board. The Annual General Meeting also resolved to re-elect Eva Malmström Jonsson as Chairperson of the Board.

In accordance with the Nomination committee’s proposal, the Annual General Meeting resolved to re-elect as auditor registered the auditing company PwC, represented by Niclas Bergenmo as the principal auditor.

Nomination Committee
It was resolved, in accordance with the Nomination Committee’s proposal, that the Nomination Committee for the 2024 Annual General Meeting shall be appointed no later than six months before the 2024 annual general meeting, where representatives of the three largest shareholders are primarily offered seats. The representative from one of the company's largest owners shall be the chairperson of the nomination committee, unless otherwise determined within the nomination committee. The Nomination Committee's work shall comply with the Swedish Code of Corporate Governance and the rules of procedure established by the General Meeting.

Authorization for the Board of Directors to resolve on new share issues
The Annual General Meeting resolved, in accordance with the Board’s proposal, to authorize the Board, at one or more occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders’ preferential rights, to resolve to issue new shares, convertibles and/or warrants. Issues may be made with or without provisions regarding payment in kind or through set-off or other provisions. The total number of shares that may be issued pursuant to the authorization (alternatively be issued through conversion of warrants and/or exercise of convertibles) shall not exceed 5,000,000 shares, which corresponds to an aggregate dilution of approximately 32 per cent calculated on the number of outstanding shares in the company. The purpose of the authorization is to increase the financial flexibility of the Company and the general flexibility of the Board of Directors. To the extent an issue is made with deviation from the shareholders’ preferential rights, the issue should be made on market terms (subject to customary new issue discount, as applicable).

The Board of Directors, the CEO, or the person that the Board appoints, shall have the right to make any adjustments in the decision required for registration. It was noted that the resolution was unanimous.

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.